Patients with hereditary angioedema visit the hospital less often with berotralstat

Patients with hereditary angioedema experienced fewer hospitalizations and ED and outpatient visits after beginning prophylactic treatment with berotralstat, according to a study presented at a recent conference. The study included 260 patients and showed a significant decrease in healthcare resource utilization, particularly for angioedema-related visits, after using berotralstat. These findings suggest that berotralstat is a cost-effective prophylactic therapy for managing HAE. While the data may have limitations, the researchers are continuing to study the benefits of berotralstat in real-world settings to further understand its positive impact on patients’ lives and the healthcare system.

Source link